Provision of alemtuzumab safety is one of the main components of pharmacovigilance
Хачанова Н. В., Бахтиярова К. З., Боyко А. Н., Власов Y. В., Давyдовскаиа М. В., Евдошенко Е. П., Захарова М. Н., Малкова Н. А., Сиверцева С. А., Спирин Н. Н., Столяров И. Д., Счмидт Т. Е., Хабиров Ф. А.
Журнал неврологии и психиатрии им. C.C. Корсакова
Т. 118, Вып. 8, С. 82-87
Опубликовано: 2018
Тип ресурса: Статья
DOI:10.17116/jnevro201811808282
Аннотация:
Modern multiple sclerosis therapy with disease-modifying drugs is characterized by the risks of dangerous infectious complications. In the last 5 years, there have been several reports of severe, sometimes lethal, listeriosis infection in patients treated with alemtuzumab. This article presents a clinical case of lethal listeriosis meningoencephalitis, which developed within 7 days after the completion of the first cycle of alemtuzumab therapy. In January 2018, a meeting of the expert Council was held, at which the clinical recommendations published in 2017 were revised and updated. © 2018, Media Sphera Publishing Group. All Rights Reserved.
Ключевые слова:
Alemtuzumab; Listeriosis; Multiple sclerosis
alemtuzumab; alemtuzumab; Article; drug safety; drug surveillance program; human; infection risk; Listeria meningitis; multiple sclerosis; drug surveillance program; meningoencephalitis; multiple sclerosis; Alemtuzumab; Humans; Meningoencephalitis; Multiple Sclerosis; Pharmacovigilance
Язык текста: Русский
ISSN: 2309-4729
Хачанова Н. В.
Бахтиярова К. З.
Боyко А. Н.
Власов Y. В.
Давyдовскаиа М. В.
Евдошенко Е. П.
Захарова М. Н.
Малкова Н. А.
Сиверцева С. А.
Спирин Н. Н.
Столяров И. Д.
Счмидт Т. Е.
Хабиров Ф. А.
Khachanova N. V.
Bakhtiyarova K. Z.
Boyko A. N.
Vlasov Y. V.
Davydovskaia M. V.
Evdoshenko E. P.
Zakharova M. N.
Malkova N. A.
Sivertseva S. A.
Spirin N. N.
Stolyarov I. D.
Schmidt T. E.
Khabirov F. A.
Provision of alemtuzumab safety is one of the main components of pharmacovigilance
Текст визуальный непосредственный
Журнал неврологии и психиатрии им. C.C. Корсакова
Издательство Медиа Сфера
Т. 118, Вып. 8 С. 82-87
2018
Статья
Alemtuzumab Listeriosis Multiple sclerosis
alemtuzumab alemtuzumab Article drug safety drug surveillance program human infection risk Listeria meningitis multiple sclerosis drug surveillance program meningoencephalitis multiple sclerosis Alemtuzumab Humans Meningoencephalitis Multiple Sclerosis Pharmacovigilance
Modern multiple sclerosis therapy with disease-modifying drugs is characterized by the risks of dangerous infectious complications. In the last 5 years, there have been several reports of severe, sometimes lethal, listeriosis infection in patients treated with alemtuzumab. This article presents a clinical case of lethal listeriosis meningoencephalitis, which developed within 7 days after the completion of the first cycle of alemtuzumab therapy. In January 2018, a meeting of the expert Council was held, at which the clinical recommendations published in 2017 were revised and updated. © 2018, Media Sphera Publishing Group. All Rights Reserved.